ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”

Grant

Awarded By

Total Award Amount

  • 11700.00

    • Direct Costs

  • 9000.00

    • Sponsor Award Id

    • Contributor

  • Elizabeth Alva   Principal Investigator  
  • Emily Johnston   Investigator  
  • Hilary Haines   Investigator  
  • Jamie Aye   Investigator  
  • Joseph Chewning III M.D.   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Matthew Kutny M.D.   Investigator